BlackRock Virginia Municipal Bond Trust
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BHV research report →
Price Chart
About the company
The BlackRock Virginia Municipal Bond Trust (BHV) functions as a closed-end mutual fund, concentrating its investments within the fixed-income sector. Launched by BlackRock, Inc. , the fund's investment management is handled by BlackRock Advisors, LLC.
- CEO
- John Perlowski
- IPO
- 2002
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on BHV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.87M
- P/E
- -625.50
- PEG
- 0.55
- P/S
- 18.49
- P/B
- 1.09
- EV/EBITDA
- 63.82
- Div Yield
- 4.51%
- Gross Margin
- 76.53%
- Op Margin
- 50.48%
- Net Margin
- -2.49%
- ROE
- -0.15%
- ROIC
- 1.80%
Latest fiscal year · YoY change
- Revenue
- $1.00M+9.4%
- Gross Profit
- $742.83K-19.0%
- Op Income
- $-964,292
- Net Income
- $-1,493,073-316.2%
- EPS
- $-0.94-318.6%
- OCF Growth
- -79.8%
- FCF Growth
- -79.8%
- 52W High
- $13.30
- 52W Low
- $10.01
- 50D MA
- $12.60
- 200D MA
- $11.33
- Beta
- 0.99
- RSI (14)
- 46
- Avg Volume
- 4.73K
No earnings-call transcripts are available for BHV yet.
- Free Float
- 99.8%
- Shares Outstanding
- 1.59M
- Float Shares
- 1.58M
of shares held by institutions
11 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ladenburg Thalmann Financial Services Inc. | 2.33K | 0 |
| Next Financial Holdings | 1.04K | ▲ 1.04K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 26 | Park Charles | other | 0 |
| May 8, 25 | Minar Stephen Thomas | other | 0 |
| Sep 9, 23 | Steinmetz Arthur Philip | other | 0 |
| Jul 1, 23 | Wasserman Aaron David | other | 0 |
| Mar 1, 23 | KALINOSKI MICHAEL | other | 0 |
| Mar 1, 23 | Santiago Kristi Manidis | other | 0 |
| Mar 1, 23 | OCONNOR WALTER | other | 0 |
| Sep 29, 22 | Romaglino Christian | other | 0 |
| Jun 16, 20 | Toronto Dominion Investments, Inc. | other | 0 |
| Jul 30, 21 | Flores Lorenzo | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BHV coverage
Recent articles, reports, and earnings notes.
No research on BHV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BHV report →Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
prnewswire.com · Aug 10
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
prnewswire.com · Jul 20
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
seekingalpha.com · Jul 13
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
prnewswire.com · Jun 29
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
seekingalpha.com · Jun 18
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
prnewswire.com · Jun 1
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
prnewswire.com · May 27
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com · Mar 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.